A Biosimilar OK’d for Breast Cancer Treatment

Newer Breast Cancer Meds Have Serious Cardiovascular Risks

The FDA approved Ogivri (trastuzumab-dkst), a biosimilar drug to Herceptin (trastuzumab), to treat patients with breast or metastatic stomach cancer. Ogivri is the first biosimilar approved in the U.S. for the treatment of breast or stomach cancer.

Common side effects associated with Ogivri for the treatment of breast cancer include headache, nausea, chills, fever, infection, congestive heart failure, insomnia, cough and rash. A few side effects associated with the drug’s treatment of stomach cancer include low levels of certain white blood cells, diarrhea, fatigue and low levels of red blood cells. On the more alarming side, Ogivri may disrupt a patient’s cancer treatment and increase the risk of infection.

“The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower health care costs. This is especially important when it comes to diseases like cancer, that have a high cost burden for patients,” said FDA Commissioner Scott Gottlieb, MD.

Like Herceptin, Ogivri’s labeling contains a Black Box warning alerting doctors and patients about increased risks of heart disease, infusions reactions, lung damage, and harm to an unborn baby.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Recommend More Articles Like This?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x